Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
This report elaborates on the current development of the Neoantigen Cancer Vaccine industry thoroughly based on the international market dynamics and China's market situation.
For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.
Secondly, this report lists the major players in the industry, displaying their market positions along with the strengths and weaknesses of their products, picturing the current competitive situation of the whole market.
Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.
Please note that the figures and tables shown in the sample are just for the purpose of demonstration, which may differ from those in the final report.
Competitive Landscape:
Genocea
Agenus
Medimmune
Advaxis
Vaccibody
Gritstone Oncology
Nouscom
Brightpath Biotherapeutics
Medigene
OSE Immunotherapeutics
Neon Therapeutics
Merck
Geneos Therapeutics
Roche
Region:
-
China
-
North America
-
Europe
-
APAC
-
Latin America, Middle East and Africa
Type:
Personalized Vaccine
Off-the-shelf Neovaccines
Application:
Hospital
Clinic
Others
Table of Content
Chapter 1 Industry Overview & Development Status in Global and China Market
-
1.1 Neoantigen Cancer Vaccine Industry Overview
-
1.1.1 Neoantigen Cancer Vaccine Market Scope and Market Segments
-
1.1.2 Neoantigen Cancer Vaccine Industry Characteristics
-
1.1.3 Global and China Neoantigen Cancer Vaccine Sales Volume and Growth Rate (2017-2028)
-
1.1.4 Global and China Neoantigen Cancer Vaccine Production Value and Growth Rate (2017-2028)
-
1.2 Global Neoantigen Cancer Vaccine Market Size and Growth Rate by Type (2017-2028)
-
1.2.1 Personalized Vaccine
-
1.2.2 Off-the-shelf Neovaccines
-
1.3 Global Neoantigen Cancer Vaccine Market Size and Growth Rate by Application (2017-2028)
-
1.3.1 Hospital
-
1.3.2 Clinic
-
1.3.3 Others
-
1.4 Market Analysis by Region
-
1.4.1 North America Neoantigen Cancer Vaccine Consumption Market Size and Growth Rate (2017-2028)
-
1.4.2 Europe Neoantigen Cancer Vaccine Consumption Market Size and Growth Rate (2017-2028)
-
1.4.3 APAC Neoantigen Cancer Vaccine Consumption Market Size and Growth Rate (2017-2028)
-
1.4.4 Latin America, Middle East and Africa Neoantigen Cancer Vaccine Consumption Market Size and Growth Rate (2017-2028)
-
1.5 Global Neoantigen Cancer Vaccine Sales Volume, Price, Sales Value, Gross and Gross Margin (2017-2028)
-
1.5.1 Global Neoantigen Cancer Vaccine Sales Volume, Price, Sales Value, Gross and Gross Margin (2017-2028)
-
1.6 China Neoantigen Cancer Vaccine Sales Volume, Price, Sales Value (2017-2028)
-
1.6.1 China Neoantigen Cancer Vaccine Sales Volume, Price, Sales Value (2017-2028)
Chapter 2 Global Neoantigen Cancer Vaccine Market Trends and Competitive Landscape
-
2.1 Market Trends and Dynamics
-
2.1.1 Challenges and Restraints
-
2.1.2 Opportunities and Potentialities
-
2.1.3 Mergers and Acquisitions
-
2.2 Competitive Landscape
-
2.2.1 Market Concentration Rate Analysis
-
2.2.2 Neoantigen Cancer Vaccine Industry Porter's Five Forces Model Analysis
-
2.2.3 Neoantigen Cancer Vaccine Industry PEST Analysis
-
2.3 Neoantigen Cancer Vaccine Industry Chain Analysis
-
2.3.1 Raw Material Supplies
-
2.3.2 Neoantigen Cancer Vaccine Downstream Market Analysis
-
2.3.3 Upstream and Downstream Impacts on Neoantigen Cancer Vaccine Industry
Chapter 3 Global and China Neoantigen Cancer Vaccine Market, by Manufacturer
-
3.1 Global and China Neoantigen Cancer Vaccine Sales Volume, Sales Value and Market Share, by Manufacturer (2021&2022)
-
3.1.1 Global and China Neoantigen Cancer Vaccine Sales Volume, by Manufacturer (2021&2022)
-
3.1.2 Global and China Neoantigen Cancer Vaccine Sales Value, by Manufacturer (2021&2022)
-
3.1.3 Global and China Neoantigen Cancer Vaccine Market Share, by Manufacturer (2021&2022)
-
3.2 SWOT Analysis on Global and China Neoantigen Cancer Vaccine Market Top 3 Players
Chapter 4 Global and China Neoantigen Cancer Vaccine Market, by Type (2017-2028)
-
4.1 Neoantigen Cancer Vaccine Market Trend, by Type
-
4.2 Global Neoantigen Cancer Vaccine Sales Volume, Sales Value, Market Share and Price Trend, by Type
-
4.2.1 Global Neoantigen Cancer Vaccine Sales Volume and Market Share, by Type (2017-2028)
-
4.2.2 Global Neoantigen Cancer Vaccine Sales Value and Market Share, by Type (2017-2028)
-
4.2.3 Global Neoantigen Cancer Vaccine Price Trend, by Type (2017-2028)
-
4.3 China Neoantigen Cancer Vaccine Sales Volume, Sales Value, Market Share and Price Trend, by Type
-
4.3.1 China Neoantigen Cancer Vaccine Sales Volume and Market Share, by Type (2017-2028)
-
4.3.2 China Neoantigen Cancer Vaccine Sales Value and Market Share, by Type (2017-2028)
-
4.3.3 China Neoantigen Cancer Vaccine Price Trend, by Type (2017-2028)
Chapter 5 Global and China Neoantigen Cancer Vaccine Market, by Application (2017-2028)
-
5.1 Downstream Market Overview
-
5.2 Global Neoantigen Cancer Vaccine Sales Volume, Sales Value and Market Share, by Application
-
5.2.1 Global Neoantigen Cancer Vaccine Sales Volume and Market Share, by Application (2017-2028)
-
5.2.2 Global Neoantigen Cancer Vaccine Sales Value and Market Share, by Application (2017-2028)
-
5.3 China Neoantigen Cancer Vaccine Sales Volume, Sales Value and Market Share, by Application
-
5.3.1 China Neoantigen Cancer Vaccine Sales Volume and Market Share, by Application (2017-2028)
-
5.3.2 China Neoantigen Cancer Vaccine Sales Value and Market Share, by Application (2017-2028)
Chapter 6 Global Neoantigen Cancer Vaccine Production, Import, Consumption and Export, by Region (2017-2022)
-
6.1 China Neoantigen Cancer Vaccine Production, Import, Consumption and Export (2017-2022)
-
6.2 North America Neoantigen Cancer Vaccine Production, Import, Consumption and Export (2017-2022)
-
6.3 Europe Neoantigen Cancer Vaccine Production, Import, Consumption and Export (2017-2022)
-
6.4 APAC Neoantigen Cancer Vaccine Production, Import, Consumption and Export (2017-2022)
-
6.5 Latin America, Middle East and Africa Neoantigen Cancer Vaccine Production, Import, Consumption and Export (2017-2022)
Chapter 7 North America Neoantigen Cancer Vaccine Market Analysis
-
7.1 North America Neoantigen Cancer Vaccine Market, by Type
-
7.2 North America Neoantigen Cancer Vaccine Market, by Application
-
7.3 North America Neoantigen Cancer Vaccine Market Analysis and Forecast, by Country
-
7.3.1 United States Neoantigen Cancer Vaccine Sales Volume, Sales Value and Growth Rate (2017-2028)
-
7.3.2 Canada Neoantigen Cancer Vaccine Sales Volume, Sales Value and Growth Rate (2017-2028)
-
7.3.3 Mexico Neoantigen Cancer Vaccine Sales Volume, Sales Value and Growth Rate (2017-2028)
Chapter 8 Europe Neoantigen Cancer Vaccine Market Analysis
-
8.1 Europe Neoantigen Cancer Vaccine Market, by Type
-
8.2 Europe Neoantigen Cancer Vaccine Market, by Application
-
8.3 Europe Neoantigen Cancer Vaccine Market Analysis and Forecast, by Country
-
8.3.1 Germany Neoantigen Cancer Vaccine Sales Volume, Sales Value and Growth Rate (2017-2028)
-
8.3.2 UK Neoantigen Cancer Vaccine Sales Volume, Sales Value and Growth Rate (2017-2028)
-
8.3.3 France Neoantigen Cancer Vaccine Sales Volume, Sales Value and Growth Rate (2017-2028)
-
8.3.4 Italy Neoantigen Cancer Vaccine Sales Volume, Sales Value and Growth Rate (2017-2028)
-
8.3.5 Nordic Countries Neoantigen Cancer Vaccine Sales Volume, Sales Value and Growth Rate (2017-2028)
-
8.3.6 Spain Neoantigen Cancer Vaccine Sales Volume, Sales Value and Growth Rate (2017-2028)
-
8.3.7 Belgium Neoantigen Cancer Vaccine Sales Volume, Sales Value and Growth Rate (2017-2028)
-
8.3.8 Poland Neoantigen Cancer Vaccine Sales Volume, Sales Value and Growth Rate (2017-2028)
-
8.3.9 Russia Neoantigen Cancer Vaccine Sales Volume, Sales Value and Growth Rate (2017-2028)
-
8.3.10 Turkey Neoantigen Cancer Vaccine Sales Volume, Sales Value and Growth Rate (2017-2028)
Chapter 9 APAC Neoantigen Cancer Vaccine Market Analysis
-
9.1 APAC Neoantigen Cancer Vaccine Market, by Type
-
9.2 APAC Neoantigen Cancer Vaccine Market, by Application
-
9.3 APAC Neoantigen Cancer Vaccine Market Analysis and Forecast, by Country
-
9.3.1 China Neoantigen Cancer Vaccine Sales Volume, Sales Value and Growth Rate (2017-2028)
-
9.3.2 Japan Neoantigen Cancer Vaccine Sales Volume, Sales Value and Growth Rate (2017-2028)
-
9.3.3 Australia and New Zealand Neoantigen Cancer Vaccine Sales Volume, Sales Value and Growth Rate (2017-2028)
-
9.3.4 India Neoantigen Cancer Vaccine Sales Volume, Sales Value and Growth Rate (2017-2028)
-
9.3.5 ASEAN Countries Neoantigen Cancer Vaccine Sales Volume, Sales Value and Growth Rate (2017-2028)
-
9.3.6 South Korea Neoantigen Cancer Vaccine Sales Volume, Sales Value and Growth Rate (2017-2028)
Chapter 10 Latin America, Middle East and Africa Neoantigen Cancer Vaccine Market Analysis
-
10.1 Latin America, Middle East and Africa Neoantigen Cancer Vaccine Market, by Type
-
10.2 Latin America, Middle East and Africa Neoantigen Cancer Vaccine Market, by Application
-
10.3 Latin America, Middle East and Africa Neoantigen Cancer Vaccine Market Analysis and Forecast, by Country
-
10.3.1 GCC Countries Neoantigen Cancer Vaccine Sales Volume, Sales Value and Growth Rate (2017-2028)
-
10.3.2 Brazil Neoantigen Cancer Vaccine Sales Volume, Sales Value and Growth Rate (2017-2028)
-
10.3.3 Nigeria Neoantigen Cancer Vaccine Sales Volume, Sales Value and Growth Rate (2017-2028)
-
10.3.4 South Africa Neoantigen Cancer Vaccine Sales Volume, Sales Value and Growth Rate (2017-2028)
-
10.3.5 Argentina Neoantigen Cancer Vaccine Sales Volume, Sales Value and Growth Rate (2017-2028)
Chapter 11 Global and China Neoantigen Cancer Vaccine Company Profiles
-
11.1 Genocea
-
11.1.1 Genocea Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.1.2 Genocea Neoantigen Cancer Vaccine Product Profiles, Application and Specification
-
11.1.3 Genocea Neoantigen Cancer Vaccine Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.2 Agenus
-
11.2.1 Agenus Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.2.2 Agenus Neoantigen Cancer Vaccine Product Profiles, Application and Specification
-
11.2.3 Agenus Neoantigen Cancer Vaccine Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.3 Medimmune
-
11.3.1 Medimmune Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.3.2 Medimmune Neoantigen Cancer Vaccine Product Profiles, Application and Specification
-
11.3.3 Medimmune Neoantigen Cancer Vaccine Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.4 Advaxis
-
11.4.1 Advaxis Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.4.2 Advaxis Neoantigen Cancer Vaccine Product Profiles, Application and Specification
-
11.4.3 Advaxis Neoantigen Cancer Vaccine Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.5 Vaccibody
-
11.5.1 Vaccibody Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.5.2 Vaccibody Neoantigen Cancer Vaccine Product Profiles, Application and Specification
-
11.5.3 Vaccibody Neoantigen Cancer Vaccine Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.6 Gritstone Oncology
-
11.6.1 Gritstone Oncology Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.6.2 Gritstone Oncology Neoantigen Cancer Vaccine Product Profiles, Application and Specification
-
11.6.3 Gritstone Oncology Neoantigen Cancer Vaccine Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.7 Nouscom
-
11.7.1 Nouscom Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.7.2 Nouscom Neoantigen Cancer Vaccine Product Profiles, Application and Specification
-
11.7.3 Nouscom Neoantigen Cancer Vaccine Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.8 Brightpath Biotherapeutics
-
11.8.1 Brightpath Biotherapeutics Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.8.2 Brightpath Biotherapeutics Neoantigen Cancer Vaccine Product Profiles, Application and Specification
-
11.8.3 Brightpath Biotherapeutics Neoantigen Cancer Vaccine Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.9 Medigene
-
11.9.1 Medigene Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.9.2 Medigene Neoantigen Cancer Vaccine Product Profiles, Application and Specification
-
11.9.3 Medigene Neoantigen Cancer Vaccine Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.10 OSE Immunotherapeutics
-
11.10.1 OSE Immunotherapeutics Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.10.2 OSE Immunotherapeutics Neoantigen Cancer Vaccine Product Profiles, Application and Specification
-
11.10.3 OSE Immunotherapeutics Neoantigen Cancer Vaccine Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.11 Neon Therapeutics
-
11.11.1 Neon Therapeutics Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.11.2 Neon Therapeutics Neoantigen Cancer Vaccine Product Profiles, Application and Specification
-
11.11.3 Neon Therapeutics Neoantigen Cancer Vaccine Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.12 Merck
-
11.12.1 Merck Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.12.2 Merck Neoantigen Cancer Vaccine Product Profiles, Application and Specification
-
11.12.3 Merck Neoantigen Cancer Vaccine Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.13 Geneos Therapeutics
-
11.13.1 Geneos Therapeutics Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.13.2 Geneos Therapeutics Neoantigen Cancer Vaccine Product Profiles, Application and Specification
-
11.13.3 Geneos Therapeutics Neoantigen Cancer Vaccine Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.14 Roche
-
11.14.1 Roche Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.14.2 Roche Neoantigen Cancer Vaccine Product Profiles, Application and Specification
-
11.14.3 Roche Neoantigen Cancer Vaccine Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
Chapter 12 Neoantigen Cancer Vaccine Industry Investment Prospect and Risk Assessment
-
12.1 Neoantigen Cancer Vaccine Industry Investment Prospect Assessment
-
12.1.1 Investment Opportunities in Segmented Markets
-
12.1.2 Investment Opportunities in Regional Markets
-
12.1.3 Investment Opportunities in Subdivided Industries
-
12.2 Neoantigen Cancer Vaccine Industry Investment Risk Assessment
-
12.2.1 Competitive Risk Analysis
-
12.2.2 Technology Risk Analysis
-
12.2.3 Policies and Enterprise System Risk Analysis
List of Tables and Figures
-
Figure Global Neoantigen Cancer Vaccine Sales Volume and Growth Rate (2017-2028)
-
Figure China Neoantigen Cancer Vaccine Sales Volume and Growth Rate (2017-2028)
-
Figure Global Neoantigen Cancer Vaccine Production Value and Growth Rate (2017-2028)
-
Figure China Neoantigen Cancer Vaccine Production Value and Growth Rate (2017-2028)
-
Figure Global Neoantigen Cancer Vaccine Market Size and Growth Rate of Personalized Vaccine (2017-2028)
-
Figure Global Neoantigen Cancer Vaccine Market Size and Growth Rate of Off-the-shelf Neovaccines (2017-2028)
-
Figure Global Neoantigen Cancer Vaccine Market Size and Growth Rate of Hospital (2017-2028)
-
Figure Global Neoantigen Cancer Vaccine Market Size and Growth Rate of Clinic (2017-2028)
-
Figure Global Neoantigen Cancer Vaccine Market Size and Growth Rate of Others (2017-2028)
-
Figure North America Neoantigen Cancer Vaccine Consumption Market Size and Growth Rate (2017-2028)
-
Figure Europe Neoantigen Cancer Vaccine Consumption Market Size and Growth Rate (2017-2028)
-
Figure APAC Neoantigen Cancer Vaccine Consumption Market Size and Growth Rate (2017-2028)
-
Figure Latin America, Middle East and Africa Neoantigen Cancer Vaccine Consumption Market Size and Growth Rate (2017-2028)
-
Figure Global Neoantigen Cancer Vaccine Sales Volume, Price, Sales Value, Gross and Gross Margin (2017-2028)
-
Figure China Neoantigen Cancer Vaccine Sales Volume, Price, Sales Value (2017-2028)
-
Figure Porter's Five Forces Model Analysis
-
Figure Industry PEST Analysis
-
Table Global and China Neoantigen Cancer Vaccine Sales Volume, by Manufacturer (2021&2022)
-
Table Global and China Neoantigen Cancer Vaccine Sales Value, by Manufacturer (2021&2022)
-
Table Global and China Neoantigen Cancer Vaccine Market Share, by Manufacturer (2021&2022)
-
Figure Global and China Neoantigen Cancer Vaccine Market Share, by Manufacturer in 2021
-
Figure Global and China Neoantigen Cancer Vaccine Market Share, by Manufacturer in 2022
-
Table Global Neoantigen Cancer Vaccine Sales Volume, by Type (2017-2028)
-
Table Global Neoantigen Cancer Vaccine Sales Volume Share, by Type (2017-2028)
-
Figure Global Neoantigen Cancer Vaccine Sales Volume Share, by Type (2017-2028)
-
Table Global Neoantigen Cancer Vaccine Sales Value, by Type (2017-2028)
-
Table Global Neoantigen Cancer Vaccine Sales Value Share, by Type (2017-2028)
-
Figure Global Neoantigen Cancer Vaccine Price Trend, by Type (2017-2028)
-
Table China Neoantigen Cancer Vaccine Sales Volume, by Type (2017-2028)
-
Table China Neoantigen Cancer Vaccine Sales Volume Share, by Type (2017-2028)
-
Figure China Neoantigen Cancer Vaccine Sales Volume Share, by Type (2017-2028)
-
Table China Neoantigen Cancer Vaccine Sales Value, by Type (2017-2028)
-
Table China Neoantigen Cancer Vaccine Sales Value Share, by Type (2017-2028)
-
Figure China Neoantigen Cancer Vaccine Price Trend, by Type (2017-2028)
-
Table Global Neoantigen Cancer Vaccine Sales Volume, by Application (2017-2028)
-
Table Global Neoantigen Cancer Vaccine Sales Volume Share, by Application (2017-2028)
-
Figure Global Neoantigen Cancer Vaccine Sales Volume Share, by Application (2017-2028)
-
Table Global Neoantigen Cancer Vaccine Sales Value, by Application (2017-2028)
-
Table Global Neoantigen Cancer Vaccine Sales Value Share, by Application (2017-2028)
-
Figure Global Neoantigen Cancer Vaccine Sales Value Share, by Application (2017-2028)
-
Table China Neoantigen Cancer Vaccine Sales Volume, by Application (2017-2028)
-
Table China Neoantigen Cancer Vaccine Sales Volume Share, by Application (2017-2028)
-
Figure China Neoantigen Cancer Vaccine Sales Volume Share, by Application (2017-2028)
-
Table China Neoantigen Cancer Vaccine Sales Value, by Application (2017-2028)
-
Table China Neoantigen Cancer Vaccine Sales Value Share, by Application (2017-2028)
-
Figure China Neoantigen Cancer Vaccine Sales Value Share, by Application (2017-2028)
-
Figure China Neoantigen Cancer Vaccine Production, Import, Consumption and Export (2017-2022)
-
Figure North America Neoantigen Cancer Vaccine Production, Import, Consumption and Export (2017-2022)
-
Figure Europe Neoantigen Cancer Vaccine Production, Import, Consumption and Export (2017-2022)
-
Figure APAC Neoantigen Cancer Vaccine Production, Import, Consumption and Export (2017-2022)
-
Figure Latin America, Middle East and Africa Neoantigen Cancer Vaccine Production, Import, Consumption and Export (2017-2022)
-
Table North America Neoantigen Cancer Vaccine Sales Volume, by Type (2017-2028)
-
Table North America Neoantigen Cancer Vaccine Sales Volume Share, by Type (2017-2028)
-
Figure North America Neoantigen Cancer Vaccine Sales Volume Share, by Type (2017-2028)
-
Table North America Neoantigen Cancer Vaccine Sales Volume, by Application (2017-2028)
-
Table North America Neoantigen Cancer Vaccine Sales Volume Share, by Application (2017-2028)
-
Figure North America Neoantigen Cancer Vaccine Sales Volume Share, by Application (2017-2028)
-
Figure United States Neoantigen Cancer Vaccine Sales Volume and Growth Rate (2017-2028)
-
Figure United States Neoantigen Cancer Vaccine Sales Value and Growth Rate (2017-2028)
-
Figure Canada Neoantigen Cancer Vaccine Sales Volume and Growth Rate (2017-2028)
-
Figure Canada Neoantigen Cancer Vaccine Sales Value and Growth Rate (2017-2028)
-
Figure Mexico Neoantigen Cancer Vaccine Sales Volume and Growth Rate (2017-2028)
-
Figure Mexico Neoantigen Cancer Vaccine Sales Value and Growth Rate (2017-2028)
-
Table Europe Neoantigen Cancer Vaccine Sales Volume, by Type (2017-2028)
-
Table Europe Neoantigen Cancer Vaccine Sales Volume Share, by Type (2017-2028)
-
Figure Europe Neoantigen Cancer Vaccine Sales Volume Share, by Type (2017-2028)
-
Table Europe Neoantigen Cancer Vaccine Sales Volume, by Application (2017-2028)
-
Table Europe Neoantigen Cancer Vaccine Sales Volume Share, by Application (2017-2028)
-
Figure Europe Neoantigen Cancer Vaccine Sales Volume Share, by Application (2017-2028)
-
Figure Germany Neoantigen Cancer Vaccine Sales Volume and Growth Rate (2017-2028)
-
Figure Germany Neoantigen Cancer Vaccine Sales Value and Growth Rate (2017-2028)
-
Figure UK Neoantigen Cancer Vaccine Sales Volume and Growth Rate (2017-2028)
-
Figure UK Neoantigen Cancer Vaccine Sales Value and Growth Rate (2017-2028)
-
Figure France Neoantigen Cancer Vaccine Sales Volume and Growth Rate (2017-2028)
-
Figure France Neoantigen Cancer Vaccine Sales Value and Growth Rate (2017-2028)
-
Figure Italy Neoantigen Cancer Vaccine Sales Volume and Growth Rate (2017-2028)
-
Figure Italy Neoantigen Cancer Vaccine Sales Value and Growth Rate (2017-2028)
-
Figure Nordic Countries Neoantigen Cancer Vaccine Sales Volume and Growth Rate (2017-2028)
-
Figure Nordic Countries Neoantigen Cancer Vaccine Sales Value and Growth Rate (2017-2028)
-
Figure Spain Neoantigen Cancer Vaccine Sales Volume and Growth Rate (2017-2028)
-
Figure Spain Neoantigen Cancer Vaccine Sales Value and Growth Rate (2017-2028)
-
Figure Belgium Neoantigen Cancer Vaccine Sales Volume and Growth Rate (2017-2028)
-
Figure Belgium Neoantigen Cancer Vaccine Sales Value and Growth Rate (2017-2028)
-
Figure Poland Neoantigen Cancer Vaccine Sales Volume and Growth Rate (2017-2028)
-
Figure Poland Neoantigen Cancer Vaccine Sales Value and Growth Rate (2017-2028)
-
Figure Russia Neoantigen Cancer Vaccine Sales Volume and Growth Rate (2017-2028)
-
Figure Russia Neoantigen Cancer Vaccine Sales Value and Growth Rate (2017-2028)
-
Figure Turkey Neoantigen Cancer Vaccine Sales Volume and Growth Rate (2017-2028)
-
Figure Turkey Neoantigen Cancer Vaccine Sales Value and Growth Rate (2017-2028)
-
Table APAC Neoantigen Cancer Vaccine Sales Volume, by Type (2017-2028)
-
Table APAC Neoantigen Cancer Vaccine Sales Volume Share, by Type (2017-2028)
-
Figure APAC Neoantigen Cancer Vaccine Sales Volume Share, by Type (2017-2028)
-
Table APAC Neoantigen Cancer Vaccine Sales Volume, by Application (2017-2028)
-
Table APAC Neoantigen Cancer Vaccine Sales Volume Share, by Application (2017-2028)
-
Figure APAC Neoantigen Cancer Vaccine Sales Volume Share, by Application (2017-2028)
-
Figure China Neoantigen Cancer Vaccine Sales Volume and Growth Rate (2017-2028)
-
Figure China Neoantigen Cancer Vaccine Sales Value and Growth Rate (2017-2028)
-
Figure Japan Neoantigen Cancer Vaccine Sales Volume and Growth Rate (2017-2028)
-
Figure Japan Neoantigen Cancer Vaccine Sales Value and Growth Rate (2017-2028)
-
Figure Australia and New Zealand Neoantigen Cancer Vaccine Sales Volume and Growth Rate (2017-2028)
-
Figure Australia and New Zealand Neoantigen Cancer Vaccine Sales Value and Growth Rate (2017-2028)
-
Figure India Neoantigen Cancer Vaccine Sales Volume and Growth Rate (2017-2028)
-
Figure India Neoantigen Cancer Vaccine Sales Value and Growth Rate (2017-2028)
-
Figure ASEAN Countries Neoantigen Cancer Vaccine Sales Volume and Growth Rate (2017-2028)
-
Figure ASEAN Countries Neoantigen Cancer Vaccine Sales Value and Growth Rate (2017-2028)
-
Figure South Korea Neoantigen Cancer Vaccine Sales Volume and Growth Rate (2017-2028)
-
Figure South Korea Neoantigen Cancer Vaccine Sales Value and Growth Rate (2017-2028)
-
Table Latin America, Middle East and Africa Neoantigen Cancer Vaccine Sales Volume, by Type (2017-2028)
-
Table Latin America, Middle East and Africa Neoantigen Cancer Vaccine Sales Volume Share, by Type (2017-2028)
-
Figure Latin America, Middle East and Africa Neoantigen Cancer Vaccine Sales Volume Share, by Type (2017-2028)
-
Table Latin America, Middle East and Africa Neoantigen Cancer Vaccine Sales Volume, by Application (2017-2028)
-
Table Latin America, Middle East and Africa Neoantigen Cancer Vaccine Sales Volume Share, by Application (2017-2028)
-
Figure Latin America, Middle East and Africa Neoantigen Cancer Vaccine Sales Volume Share, by Application (2017-2028)
-
Figure GCC Countries Neoantigen Cancer Vaccine Sales Volume and Growth Rate (2017-2028)
-
Figure GCC Countries Neoantigen Cancer Vaccine Sales Value and Growth Rate (2017-2028)
-
Figure Brazil Neoantigen Cancer Vaccine Sales Volume and Growth Rate (2017-2028)
-
Figure Brazil Neoantigen Cancer Vaccine Sales Value and Growth Rate (2017-2028)
-
Figure Nigeria Neoantigen Cancer Vaccine Sales Volume and Growth Rate (2017-2028)
-
Figure Nigeria Neoantigen Cancer Vaccine Sales Value and Growth Rate (2017-2028)
-
Figure South Africa Neoantigen Cancer Vaccine Sales Volume and Growth Rate (2017-2028)
-
Figure South Africa Neoantigen Cancer Vaccine Sales Value and Growth Rate (2017-2028)
-
Figure Argentina Neoantigen Cancer Vaccine Sales Volume and Growth Rate (2017-2028)
-
Figure Argentina Neoantigen Cancer Vaccine Sales Value and Growth Rate (2017-2028)
-
Table Genocea Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Genocea Product Profiles, Application and Specification
-
Table Genocea Neoantigen Cancer Vaccine Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table Agenus Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Agenus Product Profiles, Application and Specification
-
Table Agenus Neoantigen Cancer Vaccine Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table Medimmune Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Medimmune Product Profiles, Application and Specification
-
Table Medimmune Neoantigen Cancer Vaccine Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table Advaxis Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Advaxis Product Profiles, Application and Specification
-
Table Advaxis Neoantigen Cancer Vaccine Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table Vaccibody Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Vaccibody Product Profiles, Application and Specification
-
Table Vaccibody Neoantigen Cancer Vaccine Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table Gritstone Oncology Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Gritstone Oncology Product Profiles, Application and Specification
-
Table Gritstone Oncology Neoantigen Cancer Vaccine Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table Nouscom Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Nouscom Product Profiles, Application and Specification
-
Table Nouscom Neoantigen Cancer Vaccine Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table Brightpath Biotherapeutics Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Brightpath Biotherapeutics Product Profiles, Application and Specification
-
Table Brightpath Biotherapeutics Neoantigen Cancer Vaccine Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table Medigene Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Medigene Product Profiles, Application and Specification
-
Table Medigene Neoantigen Cancer Vaccine Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table OSE Immunotherapeutics Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table OSE Immunotherapeutics Product Profiles, Application and Specification
-
Table OSE Immunotherapeutics Neoantigen Cancer Vaccine Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table Neon Therapeutics Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Neon Therapeutics Product Profiles, Application and Specification
-
Table Neon Therapeutics Neoantigen Cancer Vaccine Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table Merck Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Merck Product Profiles, Application and Specification
-
Table Merck Neoantigen Cancer Vaccine Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table Geneos Therapeutics Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Geneos Therapeutics Product Profiles, Application and Specification
-
Table Geneos Therapeutics Neoantigen Cancer Vaccine Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table Roche Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Roche Product Profiles, Application and Specification
-
Table Roche Neoantigen Cancer Vaccine Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
